Short-term Effectiveness of Gabapentin Versus Placebo in Acute Lumbosacral Radiculalgia by Herniation Disc (GRADE) (GRADE)

  • STATUS
    Recruiting
  • End date
    Feb 27, 2025
  • participants needed
    144
  • sponsor
    Lille Catholic University
Updated on 27 April 2022

Summary

The study consists in evaluating the analgesic efficacy of Gabapentin versus Placebo in the short term (72h) acute lumbosacral radiculalgia due to disc herniation.

In addition to the usual analgesic treatment, the patient will receive gabapentin or placebo.

During the three days of treatment, an evaluation of the pain and the tolerance will be performed within the two groups: experimental and control.

Details
Condition Radiculopathy of Lumbosacral Spine Due to Disc Disorder
Treatment Placebo, Gabapentin 300mg
Clinical Study IdentifierNCT04865042
SponsorLille Catholic University
Last Modified on27 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Radiculalgia or lumboradiculalgia less than 3 months (pain of a lower limb systematized to a radicular territory, possibly associated with lumbar pain)
Inpatient management for a minimum of 72 hours after inclusion
Initial radiculalgia VAS ≥ 4 (moderate to severe pain)
Concordant disc herniation between clinical symptomatology and imaging (CT or MRI) less than 3 months
Written consent signed by the patient
Affiliation to a social security system
For women of childbearing age, use of effective contraception

Exclusion Criteria

Motor neurological deficit (≤ 3/5) or cauda equina syndrome (emergency surgical indications)
History of pre-existing neuropathic pain in the lower limb affected by radiculalgia
Lumbar infiltration performed within 72 hours prior to inclusion or unable to be performed after 72 hours
Patient already on Gabapentin or Pregabalin, or having taken these treatments in the 7 days prior to inclusion
Contraindication to Gabapentin (Hypersensitivity to the active substance or to any of the excipients: corn starch, talc, yellow iron oxide, titanium dioxide, sodium lauryl sulfate, gelatin, shellac, propylene glycol, black iron oxide and potassium hydroxide)
Creatinine clearance < 30ml/min
Hemodialysis patient
Body weight < 50kgs
Transplant patient
Patient under guardianship or curatorship
Pregnant or breastfeeding woman
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note